CRISPR & Cas Genes Market - Global Forecast 2026-2032

The CRISPR & Cas Genes Market is projected to reach USD 5.72 Billion in 2026. It is expected to continue growing at a CAGR of 13.31%, reaching USD 12.17 Billion by 2032.

CRISPR and Cas genes have advanced from a foundational genome-editing discovery to a commercially relevant platform used across human therapeutics, molecular diagnostics, agriculture, functional genomics, and industrial biotechnology. The field is anchored by programmable nucleases such as Cas9, Cas12, and Cas13, along with base-editing, prime-editing, and epigenome-editing systems designed to improve precision, reduce double-strand break dependency, and expand the range of actionable genetic targets.

Commercial confidence strengthened after regulatory approvals of CRISPR-based medicines for sickle cell disease and transfusion-dependent beta thalassemia in major jurisdictions, validating that ex vivo gene editing can meet rigorous safety, efficacy, and manufacturing standards. Academic institutes, contract research organizations, biotechnology developers, pharmaceutical manufacturers, diagnostic laboratories, and agricultural research centers are expanding CRISPR workflows for target discovery, cell therapy engineering, disease modeling, crop trait development, and rapid nucleic acid detection.

Transformative Shifts in the CRISPR & Cas Landscape

The CRISPR and Cas genes landscape is shifting from single-nuclease research tools toward integrated genome-editing ecosystems that combine guide RNA design, delivery chemistry, cell processing, quality analytics, and regulatory-grade manufacturing. This transition is increasing demand for validated reagents, high-fidelity enzymes, scalable viral and non-viral delivery systems, automation-compatible workflows, and standardized off-target assessment methods.

A second transformation is the move beyond ex vivo hematology into in vivo editing, immuno-oncology, rare disease programs, regenerative medicine, crop trait development, antimicrobial research, and point-of-care diagnostics. Adoption remains shaped by delivery limitations, immune response monitoring, off-target risk management, intellectual property complexity, reimbursement readiness, biosecurity considerations, and jurisdiction-specific rules for human, animal, and agricultural genome editing.

Cumulative Impact of Artificial Intelligence on CRISPR

Artificial intelligence is becoming a cumulative force across the CRISPR value chain. Machine learning models are improving guide RNA selection, predicting on-target editing efficiency, estimating off-target activity, prioritizing disease-associated variants, and accelerating protein engineering for Cas enzymes with improved specificity, compactness, temperature tolerance, and targeting properties.

AI is also supporting experimental design, image-based phenotyping, single-cell and multi-omics analysis, clinical candidate prioritization, and manufacturing quality control. The strongest near-term value is emerging where AI is paired with high-quality wet-lab datasets, validated assays, standardized metadata, and transparent model governance, because regulators, clinicians, and research partners require reproducible evidence rather than algorithmic claims alone.

Key Regional Insights for CRISPR & Cas Genes

North America remains a leading region for CRISPR and Cas genes due to deep biotechnology financing, major academic medical centers, advanced biomanufacturing capacity, active clinical trial infrastructure, and established regulatory pathways for cell and gene therapies. The United States is the core engine for therapeutic gene editing, functional genomics, diagnostics, and advanced therapy manufacturing, while Canada contributes strengths in genomics research, stem cell science, cell therapy production, and public-private health innovation programs.

Europe is defined by strong biomedical science, coordinated medicines regulation, and notable adoption in advanced therapy medicinal products, with the European Union providing structured clinical evaluation, pharmacovigilance, and post-authorization oversight. The United Kingdom, Germany, France, Italy, and Spain support research translation through university hospitals, national genomics initiatives, clinical networks, diagnostics capabilities, and biopharma clusters focused on rare diseases, oncology, regenerative medicine, and advanced therapies.

Asia-Pacific is scaling rapidly, led by China, Japan, South Korea, India, Australia, and ASEAN economies that are investing in genomics, clinical development, agricultural biotechnology, and biomanufacturing infrastructure. Latin America is emerging through Brazil and Mexico, where infectious disease research, crop science, and academic genomics capacity are expanding. The Middle East is building genomics-led healthcare and precision medicine strategies through Gulf investments, while Africa’s opportunity is tied to capacity building, infectious disease diagnostics, food security, local research infrastructure, and equitable access to genome-editing tools.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, CRISPR demand is supported by agricultural biotechnology, infectious disease research, aquaculture applications, and rising biomedical R&D across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are using national genomics programs, precision medicine investments, biobank development, and hospital modernization to create demand for genomic testing, translational research, rare disease diagnostics, and advanced therapy partnerships.

The European Union remains central to regulatory harmonization, clinical trial oversight, data protection standards, and advanced therapy development, making it a key reference environment for compliance-led CRISPR commercialization. BRICS economies combine large patient populations, agricultural productivity needs, expanding scientific capacity, and growing biomanufacturing infrastructure, creating sustained demand across healthcare, diagnostics, livestock improvement, and crop trait development.

G7 markets set the pace for intellectual property activity, reimbursement evaluation, clinical adoption, ethical governance, and manufacturing standards, while NATO-aligned countries benefit from strong biomedical security, pathogen surveillance, dual-use governance frameworks, and coordinated research security priorities. Across these groups, the most successful participants are those that align product claims, clinical evidence, data packages, biosafety practices, and market access strategies with local policy priorities.

Key Country Insights for CRISPR & Cas Genes

The United States leads CRISPR commercialization through FDA-regulated clinical programs, biotechnology financing, genomic medicine infrastructure, and a dense network of research institutions and advanced therapy manufacturing sites. Canada adds strengths in stem cell research, cell therapy, genomics initiatives, and health data infrastructure, while Mexico is developing translational genomics and regional manufacturing relevance. Brazil is the most influential Latin American market for agricultural biotechnology and is expanding biomedical research capacity in infectious disease, genomics, and public health applications.

In Europe, the United Kingdom has been an early regulator of CRISPR-based therapy and maintains strong genomics infrastructure, clinical research networks, and advanced therapy capabilities. Germany and France provide mature biopharma, diagnostics, academic research, and manufacturing ecosystems, while Italy and Spain contribute hospital-based clinical networks and growing advanced therapy capacity. Russia maintains scientific expertise in molecular biology and genetics, although international collaboration, procurement, and market access are affected by geopolitical and regulatory constraints.

China is a major force in CRISPR research output, clinical exploration, agricultural biotechnology, and manufacturing scale. India is expanding through cost-efficient research services, vaccine and biopharma capabilities, genomics programs, and agricultural biotechnology needs. Japan emphasizes high-quality translational science, regenerative medicine frameworks, and precision healthcare, while Australia supports clinical research, genomics implementation, and agricultural innovation. South Korea combines strong biotechnology investment, digital health infrastructure, and advanced cell and gene therapy capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically meaningful applications where CRISPR offers clear advantages over conventional approaches, including durable correction of monogenic disease, engineered immune cells, validated functional genomics, rapid molecular diagnostics, and targeted crop trait improvement. Portfolio decisions should be guided by delivery feasibility, edit durability, manufacturability, payer relevance, clinical workflow fit, biosafety requirements, and defensible intellectual property.

Organizations should invest in high-fidelity editing systems, validated off-target and on-target assessment, scalable GMP manufacturing, robust release testing, and AI-supported design platforms with transparent data governance. Partnerships with academic medical centers, contract development and manufacturing organizations, diagnostic laboratories, agricultural institutes, patient groups, and regional regulatory experts can shorten development timelines while reducing technical, compliance, and access-related risks.

Research Methodology

This executive summary is developed using a secondary research framework that synthesizes public regulatory decisions, peer-reviewed scientific literature, clinical trial registries, patent publications, government genomics initiatives, bioethics guidance, and established biotechnology and life sciences databases. Emphasis is placed on verifiable developments, including approved CRISPR-based therapies, recognized Cas enzyme classes, documented regional biotechnology capabilities, and published evidence on delivery, specificity, and safety assessment.

Insights are triangulated across technology, application, end-user, regulatory environment, and geography to identify market direction without relying on unsupported claims. The methodology prioritizes data integrity, regulatory relevance, reproducibility, scientific consensus, and practical commercial interpretation for decision-makers in biotechnology, pharmaceuticals, diagnostics, agriculture, research tools, and advanced therapy manufacturing.

Conclusion

The CRISPR and Cas genes market is entering a more disciplined phase in which scientific capability must be matched by clinical validation, delivery innovation, manufacturing scale, ethical oversight, and responsible governance. Regulatory approvals have confirmed the platform’s therapeutic potential, but long-term leadership will depend on safety evidence, durable clinical outcomes, access models, and application-specific execution.

Organizations that combine robust genome-editing science with AI-enabled discovery, regional regulatory intelligence, scalable manufacturing, and transparent risk management will be best positioned to capture value. The next wave of development will be shaped by in vivo editing, next-generation Cas systems, precision diagnostics, multiplex functional genomics, and expanded use in agriculture and industrial biotechnology.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. CRISPR & Cas Genes Market, by Cas Type

7.1. Introduction
7.2. Cas12
7.3. Cas13
7.4. Cas14
7.5. Cas9

8. CRISPR & Cas Genes Market, by Delivery Method

8.1. Introduction
8.2. Electroporation
8.3. Liposome Transfection
8.4. Microinjection
8.5. Nanoparticle Delivery
8.5.1. Lipid Nanoparticles
8.5.2. Polymer Nanoparticles
8.6. Viral Vector
8.6.1. Adeno Associated Virus
8.6.2. Adenovirus
8.6.3. Lentivirus

9. CRISPR & Cas Genes Market, by Technology

9.1. Introduction
9.2. Ex Vivo
9.2.1. Cell Line Engineering
9.2.2. Primary Cell Modification
9.3. In Vivo
9.3.1. Clinical Trials
9.3.2. Preclinical Models

10. CRISPR & Cas Genes Market, by Application

10.1. Introduction
10.2. Agricultural Biotechnology
10.3. Animal Model Development
10.4. Diagnostics
10.4.1. Disease Detection
10.4.2. Genetic Screening
10.5. Gene Editing
10.5.1. Research Applications
10.5.2. Therapeutic Applications
10.6. Gene Therapy

11. CRISPR & Cas Genes Market, by End User

11.1. Introduction
11.2. Biotechnology Companies
11.3. Contract Research Organizations
11.4. Pharmaceutical Companies
11.5. Research Institutes

12. CRISPR & Cas Genes Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. CRISPR & Cas Genes Market, by Group

13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC

14. CRISPR & Cas Genes Market, by Country

14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Addgene
16.2. AstraZeneca PLC
16.3. Bayer AG
16.4. Beam Therapeutics Inc.
16.5. Beckman Coulter, Inc.
16.6. Calyxt, Inc.
16.7. Caribou Biosciences, Inc.
16.8. Cellectis plant sciences, Inc.
16.9. Corteva, Inc.
16.10. CRISPR Therapeutics AG
16.11. Danaher Corporation
16.12. Editas Medicine, Inc.
16.13. GenScript Biotech Corporation
16.14. Hera Biolabs
16.15. Inscripta, Inc.
16.16. Integrated DNA Technologies, Inc.
16.17. Intellia Therapeutics, Inc.
16.18. Lonza Group Ltd.
16.19. Mammoth Biosciences, Inc.
16.20. Merck KGaA
16.21. OriGene Technologies, Inc.
16.22. PerkinElmer, Inc.
16.23. Sangamo Therapeutics, Inc.
16.24. Takara Bio Inc.
16.25. Thermo Fisher Scientific Inc.

List of Figures

FIGURE 1. GLOBAL CRISPR & CAS GENES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CRISPR & CAS GENES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CRISPR & CAS GENES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CRISPR & CAS GENES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL CRISPR & CAS GENES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CAS12 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CAS12 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CAS12 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CAS13 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CAS13 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CAS13 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CAS14 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CAS14 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CAS14 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CAS9 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CAS9 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CAS9 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ELECTROPORATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ELECTROPORATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ELECTROPORATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL LIPOSOME TRANSFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL LIPOSOME TRANSFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL LIPOSOME TRANSFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MICROINJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MICROINJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MICROINJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL POLYMER NANOPARTICLES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL POLYMER NANOPARTICLES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL POLYMER NANOPARTICLES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LENTIVIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LENTIVIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LENTIVIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PRECLINICAL MODELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PRECLINICAL MODELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PRECLINICAL MODELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ANIMAL MODEL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ANIMAL MODEL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ANIMAL MODEL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DISEASE DETECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL DISEASE DETECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL DISEASE DETECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL GENETIC SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GENETIC SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GENETIC SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL THERAPEUTIC APPLICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL THERAPEUTIC APPLICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 120. EUROPE CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. EUROPE CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 123. EUROPE CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 124. EUROPE CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 125. EUROPE CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 126. EUROPE CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 127. EUROPE CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 128. EUROPE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 130. EUROPE CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 131. EUROPE CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. AFRICA CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. AFRICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 158. AFRICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 159. AFRICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 160. AFRICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 161. AFRICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 162. AFRICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 163. AFRICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 164. AFRICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 165. AFRICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 166. AFRICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 167. AFRICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. NATO CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 183. NATO CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 184. NATO CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 185. NATO CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 186. NATO CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 187. NATO CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 188. NATO CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 189. NATO CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 190. NATO CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 191. NATO CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 192. NATO CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. G7 CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. G7 CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 195. G7 CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 196. G7 CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 197. G7 CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 198. G7 CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 199. G7 CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 200. G7 CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 201. G7 CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. G7 CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 203. G7 CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 204. G7 CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. BRICS CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. BRICS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 207. BRICS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 208. BRICS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 209. BRICS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 210. BRICS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 211. BRICS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 212. BRICS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 213. BRICS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. BRICS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 215. BRICS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 216. BRICS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. ASEAN CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. ASEAN CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 231. ASEAN CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 232. ASEAN CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 233. ASEAN CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 234. ASEAN CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 235. ASEAN CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 236. ASEAN CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 237. ASEAN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 238. ASEAN CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 239. ASEAN CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 240. ASEAN CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. GCC CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. GCC CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 243. GCC CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 244. GCC CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 245. GCC CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 246. GCC CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 247. GCC CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 248. GCC CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 249. GCC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 250. GCC CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 251. GCC CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 252. GCC CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 254. CHINA CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. CHINA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 256. CHINA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 257. CHINA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 258. CHINA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 259. CHINA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 260. CHINA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 261. CHINA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 262. CHINA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. CHINA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 264. CHINA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 265. CHINA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. JAPAN CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. JAPAN CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 280. JAPAN CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 281. JAPAN CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 282. JAPAN CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 283. JAPAN CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 284. JAPAN CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 285. JAPAN CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 286. JAPAN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 287. JAPAN CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 288. JAPAN CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 289. JAPAN CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. INDIA CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. INDIA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 292. INDIA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 293. INDIA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 294. INDIA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 295. INDIA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 296. INDIA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 297. INDIA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 298. INDIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 299. INDIA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 300. INDIA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 301. INDIA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. GERMANY CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. GERMANY CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 304. GERMANY CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 305. GERMANY CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 306. GERMANY CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 307. GERMANY CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 308. GERMANY CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 309. GERMANY CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 310. GERMANY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 311. GERMANY CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 312. GERMANY CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 313. GERMANY CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 316. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 317. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 318. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 319. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 328. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 329. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 331. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 334. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 335. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 338. FRANCE CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 339. FRANCE CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 340. FRANCE CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 341. FRANCE CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 342. FRANCE CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 343. FRANCE CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 344. FRANCE CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 345. FRANCE CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 346. FRANCE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 347. FRANCE CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 348. FRANCE CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 349. FRANCE CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 352. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 356. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 357. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 358. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 362. ITALY CRISPR & CAS GENES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 363. ITALY CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2017-2032 (USD MILLION)
TABLE 364. ITALY CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2017-2032 (USD MILLION)
TABLE 365. ITALY CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2017-2032 (USD MILLION)
TABLE 366. ITALY CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 367. ITALY CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 368. ITALY CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2017-2032 (USD MILLION)
TABLE 369. ITALY CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2017-2032 (USD MILLION)
TABLE 370. ITALY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2017-2032 (

Companies Mentioned

Addgene
AstraZeneca PLC
Bayer AG
Beam Therapeutics Inc.
Beckman Coulter, Inc.
Calyxt, Inc.
Caribou Biosciences, Inc.
Cellectis plant sciences, Inc.
Corteva, Inc.
CRISPR Therapeutics AG
Danaher Corporation
Editas Medicine, Inc.
GenScript Biotech Corporation
Hera Biolabs
Inscripta, Inc.
Integrated DNA Technologies, Inc.
Intellia Therapeutics, Inc.
Lonza Group Ltd.
Mammoth Biosciences, Inc.
Merck KGaA
OriGene Technologies, Inc.
PerkinElmer, Inc.
Sangamo Therapeutics, Inc.
Takara Bio Inc.
Thermo Fisher Scientific Inc.

Table Information

Report Attribute	Details
No. of Pages	190
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 5.72 Billion
Forecasted Market Value ( USD ) by 2032	$ 12.17 Billion
Compound Annual Growth Rate	13.3%
Regions Covered	Global
No. of Companies Mentioned	25

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3180EUR$3,545USD£2,719GBP €3534EUR$3,939USD£3,021GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4811EUR$5,363USD£4,113GBP €5346EUR$5,959USD£4,570GBP

Transformative Shifts in the CRISPR & Cas Landscape

Cumulative Impact of Artificial Intelligence on CRISPR

Key Regional Insights for CRISPR & Cas Genes

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Key Country Insights for CRISPR & Cas Genes

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

CRISPR Gene Editing Market - Global Forecast 2026-2032

CRISPR Technology Market - Global Forecast 2026-2032

CRISPR Technology - Global Strategic Business Report

CRISPR-based Gene Editing - Global Strategic Business Report

CRISPR-based Gene Editing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)